Healthcare
CorMedix Inc(CRMD)
Live Price
Offline$8.82
+1.73% today
1Y Change
-42.55%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $610.00M
- Revenue Growth
- +617.0%
- EPS Growth
- +850.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CorMedix Inc (CRMD) is a Healthcare stock with a market cap of $610.00M and listed on NASDAQ. The stock last traded around $8.82 and down 42.6% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +617.0%, EPS growth of +850.0%, a dividend yield of 0.0%. What stands out right now is revenue +617.0%, EPS +850.0%, free cash flow +440.6% with operating margin 48.2% and ROIC 24.9%. Valuation is more restrained than many high-expectation growth names at P/E 3.7 and price/sales 1.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines CRMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+617.0% vs +7.6% peer median
Operating Margin
Above sector median
+48.2% vs +19.4% peer median
P/E
Below sector median
3.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +617.0% and EPS at +850.0%, with operating margin around 48.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +4.1% | -2.8% | +6.5% |
2026 Mar 5, 2026 | -29.1% | +2.5% | +1.6% | +11.9% |
2025 Nov 12, 2025 | +18.8% | -1.8% | -12.2% | +2.8% |
Benchmark Edge
CRMD vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CRMD
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CRMD Max Drawdown
-58.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CRMD and SPY.
Company Overview
CorMedix Inc
NASDAQ
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, particularly in anti-infective therapies and hospital-based treatments in the United States. Its lead product, DefenCath, is an FDA-approved antimicrobial catheter lock solution containing taurolidine and heparin, designed to reduce catheter-related bloodstream infections in adult patients with kidney failure undergoing chronic hemodialysis via central venous catheters. This product serves outpatient dialysis organizations and holds a unique position as the first such approved solution in its indication. Following the acquisition of Melinta Therapeutics in August 2025, CorMedix Inc. expanded its commercial portfolio to include seven innovative anti-infective drugs: MINOCIN for injection, REZZAYO for candidemia and invasive candidiasis, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. These therapies strengthen its presence in acute care settings, infectious disease management, and hospital markets, diversifying beyond dialysis applications. Incorporated in 2006 and headquartered in Berkeley Heights, New Jersey, CorMedix Inc. operates as a single drug product segment emphasizing commercial sales and strategic investments in specialty pharmaceuticals.
- Leadership
- Mr. Joseph Todisco MBA
- Employees
- 191
- Street Address
- 389 Interpace Pkwy, Suite 450
- Mailing
- Parsippany, NJ, 07054
- Region
- Parsippany, NJ, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 3.7
- EV/EBITDA
- 3.7
- Price/Sales
- 1.9
- Price/Book
- 1.5
Growth
- Revenue
- +617.0%
- EPS
- +850.0%
- Free Cash Flow
- +440.6%
Profitability
- Gross Margin
- 88.5%
- Operating Margin
- 48.2%
- Net Margin
- 52.3%
- ROE
- 58.5%
- ROIC
- 24.9%
Balance Sheet
- Debt/Equity
- 0.37
- Current Ratio
- 2.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.